PMID- 16648573
OWN - NLM
STAT- MEDLINE
DCOM- 20060919
LR  - 20220309
IS  - 1535-7163 (Print)
IS  - 1535-7163 (Linking)
VI  - 5
IP  - 4
DP  - 2006 Apr
TI  - Enhancement of tumor thermal therapy using gold nanoparticle-assisted tumor 
      necrosis factor-alpha delivery.
PG  - 1014-20
AB  - Tumor necrosis factor-alpha (TNF-alpha) is a potent cytokine with anticancer 
      efficacy that can significantly enhance hyperthermic injury. However, TNF-alpha 
      is systemically toxic, thereby creating a need for its selective tumor delivery. 
      We used a newly developed nanoparticle delivery system consisting of 33-nm 
      polyethylene glycol-coated colloidal gold nanoparticles (PT-cAu-TNF-alpha) with 
      incorporated TNF-alpha payload (several hundred TNF-alpha molecules per 
      nanoparticle) to maximize tumor damage and minimize systemic exposure to 
      TNF-alpha. SCK mammary carcinomas grown in A/J mice were treated with 125 or 250 
      microg/kg PT-cAu-TNF-alpha alone or followed by local heating at 42.5 degrees C 
      using a water bath for 60 minutes, 4 hours after nanoparticle injection. 
      Increases in tumor growth delay were observed for both PT-cAu-TNF-alpha alone and 
      heat alone, although the most dramatic effect was found in the combination 
      treatment. Tumor blood flow was significantly suppressed 4 hours after an i.v. 
      injection of free TNF-alpha or PT-cAu-TNF-alpha. Tumor perfusion, imaged by 
      contrast enhanced ultrasonography, on days 1 and 5 after treatment revealed 
      perfusion defects after the injection of PT-cAu-TNF-alpha alone and, in many 
      regions, complete flow inhibition in tumors treated with combination treatment. 
      The combination treatment of SCK tumors in vivo reduced the in vivo/in vitro 
      tumor cell survival to 0.05% immediately following heating and to 0.005% at 18 
      hours after heating, suggesting vascular damage-mediated tumor cell killing. 
      Thermally induced tumor growth delay was enhanced by pretreatment with 
      TNF-alpha-coated gold nanoparticles when given i.v. at the proper dosage and 
      timing.
FAU - Visaria, Rachana K
AU  - Visaria RK
AD  - Department of Mechanical Engineering, University of Minnesota Medical School, 
      Minneapolis, MN 55455, USA.
FAU - Griffin, Robert J
AU  - Griffin RJ
FAU - Williams, Brent W
AU  - Williams BW
FAU - Ebbini, Emad S
AU  - Ebbini ES
FAU - Paciotti, Giulio F
AU  - Paciotti GF
FAU - Song, Chang W
AU  - Song CW
FAU - Bischof, John C
AU  - Bischof JC
LA  - eng
GR  - CA44114/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - United States
TA  - Mol Cancer Ther
JT  - Molecular cancer therapeutics
JID - 101132535
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 7440-57-5 (Gold)
RN  - MLT4718TJW (Rubidium)
SB  - IM
MH  - Animals
MH  - Biological Transport
MH  - Cell Survival/drug effects/physiology
MH  - *Gold
MH  - Hyperthermia, Induced
MH  - Mammary Neoplasms, Experimental/pathology/*therapy
MH  - Mice
MH  - Nanostructures
MH  - Rubidium/pharmacokinetics
MH  - Tumor Necrosis Factor-alpha/*pharmacokinetics/*therapeutic use
EDAT- 2006/05/02 09:00
MHDA- 2006/09/20 09:00
CRDT- 2006/05/02 09:00
PHST- 2006/05/02 09:00 [pubmed]
PHST- 2006/09/20 09:00 [medline]
PHST- 2006/05/02 09:00 [entrez]
AID - 5/4/1014 [pii]
AID - 10.1158/1535-7163.MCT-05-0381 [doi]
PST - ppublish
SO  - Mol Cancer Ther. 2006 Apr;5(4):1014-20. doi: 10.1158/1535-7163.MCT-05-0381.